Cliff Asness's TGTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 67,811 shares of TG Therapeutics, Inc. (TGTX) worth $2.45 M, representing 0.00% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 43,377 shares. Largest reduction occurred in Q4 2015, reducing 53,123 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +10,200 | New Buy | 10,200 | $5.10 |
| Q4 2013 | +32,900 | Add 322.55% | 43,100 | $3.90 |
| Q2 2014 | -25,600 | Reduce 59.40% | 17,500 | $9.37 |
| Q3 2014 | +11,400 | Add 65.14% | 28,900 | $10.66 |
| Q4 2014 | +19,500 | Add 67.47% | 48,400 | $15.85 |
| Q1 2015 | +1,100 | Add 2.27% | 49,500 | $15.47 |
| Q2 2015 | +13,560 | Add 27.39% | 63,060 | $16.59 |
| Q3 2015 | -9,937 | Reduce 15.76% | 53,123 | $10.07 |
| Q4 2015 | -53,123 | Sold Out | 0 | $0.00 |
| Q2 2017 | +10,274 | New Buy | 10,274 | $10.03 |
| Q3 2017 | +36,263 | Add 352.96% | 46,537 | $11.84 |
| Q1 2018 | +730 | Add 1.57% | 47,267 | $14.20 |
| Q2 2018 | -11,483 | Reduce 24.29% | 35,784 | $13.16 |
| Q3 2018 | -18,836 | Reduce 52.64% | 16,948 | $5.61 |
| Q4 2018 | -16,948 | Sold Out | 0 | $0.00 |
| Q4 2019 | +36,171 | New Buy | 36,171 | $11.09 |
| Q1 2020 | +8,624 | Add 23.84% | 44,795 | $9.84 |
| Q2 2020 | +24,075 | Add 53.74% | 68,870 | $19.49 |
| Q3 2020 | +7,898 | Add 11.47% | 76,768 | $26.76 |
| Q4 2020 | -5,012 | Reduce 6.53% | 71,756 | $52.02 |
| Q1 2021 | -9,148 | Reduce 12.75% | 62,608 | $48.20 |
| Q3 2021 | -12,173 | Reduce 19.44% | 50,435 | $33.27 |
| Q4 2021 | -16,354 | Reduce 32.43% | 34,081 | $19.01 |
| Q2 2022 | -34,081 | Sold Out | 0 | $0.00 |
| Q1 2023 | +43,377 | New Buy | 43,377 | $15.04 |
| Q2 2023 | +20,261 | Add 46.71% | 63,638 | $24.84 |
| Q3 2023 | -3,783 | Reduce 5.94% | 59,855 | $8.36 |
| Q4 2023 | -41,968 | Reduce 70.12% | 17,887 | $17.08 |
| Q1 2024 | +26,477 | Add 148.02% | 44,364 | $15.21 |
| Q2 2024 | -6,339 | Reduce 14.29% | 38,025 | $17.79 |
| Q3 2024 | +21,411 | Add 56.31% | 59,436 | $23.39 |
| Q4 2024 | +8,431 | Add 14.19% | 67,867 | $30.10 |
| Q1 2025 | -32,574 | Reduce 48.00% | 35,293 | $39.43 |
| Q2 2025 | -1,944 | Reduce 5.51% | 33,349 | $35.99 |
| Q3 2025 | +34,462 | Add 103.34% | 67,811 | $36.13 |
Cliff Asness's TG Therapeutics Investment FAQs
Cliff Asness first purchased TG Therapeutics, Inc. (TGTX) in Q3 2013, acquiring 10,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held TG Therapeutics, Inc. (TGTX) for 39 quarters since Q3 2013.
Cliff Asness's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2023, adding 43,377 shares worth $652,390.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 67,811 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $2.45 M.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in TG Therapeutics, Inc. (TGTX) was 76,768 shares, as reported at the end of Q3 2020.